- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about Psychedelic/Assisted Therapies
Recent news which mentions Psychedelic/Assisted Therapies
Tickers
NEWS
Tags
Latin America
Psychedelic/Assisted Therapies
Chacruna Institute for Psychedelic Plant Medicines
From Benzinga
From Benzinga
How Strategic Real Estate Investments Are Driving Psychedelic Therapy's Growth, Bridging Gaps In Mental Healthcare
June 24, 2024
From Benzinga
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
April 17, 2024
From Benzinga
Numinus Wellness Q2 2024 Revenue Declines Amid Clinic Reshuffling And Expected Industry Trends
April 15, 2024
From Benzinga
From Benzinga
Psychedelics Reform Update: Missouri's $10M Budget, Maine's & Maryland's Study Groups, Oregon's Re-Crim And More
April 05, 2024
From Benzinga
From Benzinga
Atai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic Pipeline
March 29, 2024
From Benzinga
From Benzinga
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow
March 27, 2024
From Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
From Benzinga
Psychedelics Update: Task Forces In Three States, Decrim No-Go, Arizona Psilocybin Centers, Utah And More
March 18, 2024
From Benzinga
Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review
March 16, 2024
From Benzinga
Fed Agency Grants $14M To Gilgamesh For Cardiac-Safe Ibogaine Analog Targeting Opioid Use Disorder
March 15, 2024
Tickers
NEWS
From Benzinga
From Benzinga
Psyence Biomedical Will Undertake Psilocybin Clinical Trials For Palliative Care In Australia
March 11, 2024
Tickers
PBM
From Benzinga
MindMeds Systematic Biotech Approach With New FDA Therapy Designation, 12-Week Clinical Data, Plus Expected $175M Proceeds
March 08, 2024
From Benzinga
From Benzinga
Psychedelics 2024: Veterans Blessing, Mental Health Paradigm Shift, Providers Training, Ketamine-MDMA Bonds & More
March 06, 2024
From Benzinga
Psychedelics Reform Update: Connecticut's Decriminalization, Vermont Hearings, Arizona's Psilocybin Services & More
March 01, 2024
From Benzinga
Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More
March 01, 2024
From Benzinga
GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates
February 29, 2024
From Benzinga
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Tickers
CMPS
From Benzinga
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
February 29, 2024
From Benzinga
Beckley Academy's Open-Source Psychedelic Therapy Learning Framework Is Out: What's It All About? Authoring Team Shares Insights
February 29, 2024
From Benzinga
MindMed's 2023 Financial Results And Business Recap: Milestones Amid Rising Expenses
February 28, 2024
Tickers
MNMD
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.